Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Arena Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference on January 16
SAN DIEGO , Jan. 8, 2020 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that Amit D. Munshi , the Company's President and Chief Executive Officer, will present a corporate update at the 38 th Annual J.P. Morgan Healthcare Conference on Thursday, January 16 , at 1:00 PM
View HTML
Toggle Summary Arena Pharmaceuticals Highlights Strategic Plan Driving Near and Long-term Growth with Eight Ph 2 and Ph 3 Data Readouts in 2020-21 and One New IND Per Year for the Next 5 Years
- Initiation of etrasimod Ph 2/3 program in Crohn's disease (CD) - Two additional Ph 2 etrasimod development programs in eosinophilic esophagitis (EoE) and alopecia areata (AA) - First subject dosed in APD418 Ph 1 trial in Decompensated Heart Failure (DHF) - Expanded multi-program collaboration
View HTML
Toggle Summary Arena Pharmaceuticals and Beacon Discovery Expand Strategic Relationship Focusing on Multiple Immune and Inflammatory Targets
- Selected targets (Project Cabrillo) represent new therapeutic potential across a broad range of immune and inflammatory diseases - Leveraging Beacon's world-class G protein-coupled receptor (GPCR) discovery platform to augment Arena's robust pipeline SAN DIEGO , Jan.
View HTML
Toggle Summary Arena Pharmaceuticals to Participate in Upcoming Investor Conferences
SAN DIEGO , Nov. 26, 2019 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that members of its senior management team will participate at the upcoming investor conferences: Evercore ISI HealthCONx Conference – Presenting on Tuesday, December 3 , at 11:00 AM ET in Boston
View HTML
Toggle Summary California Life Sciences Association Honors Arena Pharmaceuticals at the Pantheon 2019 DiNA™ Awards for the Deal of the Year
- Arena received the 2019 Deal of the Year Award for its global licensing agreement with United Therapeutics for ralinepag, a prostacyclin receptor agonist, in development for the treatment of pulmonary arterial hypertension (PAH) SAN DIEGO , Nov. 18, 2019 /PRNewswire/ --  Arena Pharmaceuticals,
View HTML
Toggle Summary Arena Pharmaceuticals Presented New Data Highlighting the Human Mass Balance and Metabolism Profile of Etrasimod at AAPS
- In a Human Mass Balance study, etrasimod metabolism demonstrated no major metabolites - The overall results suggest low risk for drug-drug interactions SAN DIEGO , Nov. 6, 2019 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) presented new data evaluating the human mass balance,
View HTML
Toggle Summary Arena Pharmaceuticals to Present at Upcoming Investor Conferences
SAN DIEGO , Nov. 5, 2019 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that members of its senior management team will present at the upcoming investor conferences: Credit Suisse 28th Annual Healthcare Conference – Presenting on Tuesday, November 12 , at 10:00 AM ET (
View HTML
Toggle Summary Arena Pharmaceuticals Announces First Subject Dosed in ADVISE Phase 2 Trial Evaluating Etrasimod in Atopic Dermatitis
- ADVISE clinical trial initiated and enrollment progressing - Evaluating patients with the clinical diagnosis of moderate-to-severe atopic dermatitis - Significant unmet need for an oral therapy in atopic dermatitis SAN DIEGO , Oct. 28, 2019 /PRNewswire/ --  Arena Pharmaceuticals, Inc.
View HTML
Toggle Summary Arena Pharmaceuticals Presented New Data Analyses Demonstrating the Long-Term Safety and Efficacy of Once-Daily Etrasimod in Patients with Moderately to Severely Active Ulcerative Colitis at UEG Week
- Most patients that experienced clinical response, clinical remission, or endoscopic improvement with etrasimod 2 mg in the Phase 2 OASIS trial observed sustained or improved effects up to week 46 of treatment - Etrasimod demonstrated a favorable safety profile, consistent with the double-blind
View HTML
Toggle Summary Arena Pharmaceuticals' Presence at United European Gastroenterology Week Bolsters Commitment to the Gastrointestinal Disease Community
- New open-label extension data from the Phase 2 OASIS trial for etrasimod in ulcerative colitis - Arena sponsored breakfast symposium: Will oral therapies change the IBD treatment landscape? - Visit Arena in the exhibit hall at booth #78 SAN DIEGO , Oct.
View HTML